Biosensia is an in vitro diagnostics company that has developed a novel point of care platform, RapiPlex. Biosensia’s proprietary RapiPlex platform integrates three technologies:

• A multi-channel fluidic chip
• Robust, well-established fluorescence immunoassay systems
• An integrated optical reader, providing numerical read-outs without the need for user interpretation

RapiPlex can be used for multiple point of care analytical applications, including infectious diseases, drugs of abuse (DOA) testing and cardiac markers. Other applications range through food and environment to clinical and security.

Contact Information:

Biosensia Ltd, NovaUCD,
Belfield Innovation Park, UCD
Belfield, Dublin 4, Ireland  

Website: http://www.biosensia.com/